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1.  Introduction
The Southern African Hypertension Society (SAHS) published
its first guideline in 1995 followed by a second in 2001.1,2 Since
then a number of new recommendations for the diagnosis and
management of hypertension have been published
internationally and reflected in the numerous guideline
revisions.3-7 This version remains modelled on evidence-based
links guidelines8,9 and emphasises the trend toward risk
stratification and the tighter control of BP once management
has been started.4-6
However, the SAHS Executive Committee gave only a
limited mandate for the review of its guideline in 2002.  Thus,
only the following sections have been fully revised and are
designated as new sections:
• The measurement of blood pressure (BP)
• Sustainable hypertension management and scarce resources
• Compelling indications for a specific drug class
• Comprehensive management of the complicated patient
• Strategy implications.
The remainder of the guideline remains unchanged except
for these updates.  The SAHS is in the process of revising the
entire guideline which should be complete in 2005.  The
methodology and participants for the 2001 version and this
update are given in Annexures A and B.
Hypertension is a major health challenge in South Africa.
This guideline is targeted at all health care professionals in
both the public and private health sectors.  It reflects realistic
objectives that can be applied widely and aims to diminish the
impact of hypertension in this country.  The control of
hypertension in conjunction with other major risk factors such
as cigarette smoking, dyslipidaemia and diabetes mellitus
constitutes the ideal approach to the primary prevention of
atherosclerotic disease and remains a major challenge for the
community at large.  In 2004, as this updated version goes to
press, it is clear that the trend towards comprehensive
cardiovascular risk factor management is now the
internationally accepted model of care.6
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Outcomes. Extensive data from many randomised controlled
trials have shown the benefit of treating hypertension.  The
target blood pressure (BP) for antihypertensive management
should be systolic BP < 140 mmHg, diastolic < 90 mmHg,
with minimal or no drug side-effects.  However, a lesser
reduction will elicit benefit although this is not optimal.  The
reduction of BP in the elderly and in those with severe
hypertension should be achieved gradually over 6 months.
Stricter BP control is required for patients with end organ
damage, co-existing risk factors and co-morbidity, e.g.
diabetes mellitus.  Co-existent risk factors should also be
controlled.
Benefits. Reduction in risk of stroke, cardiac failure, renal
insufficiency and probably coronary artery disease.  The
major precautions and contraindications to each
antihypertensive drug recommended are listed.
Recommendations. Correct BP measurement procedure is
described.  Evaluation of cardiovascular risk factors and
recommendations for antihypertensive therapy are
stipulated.  The total cardiovascular disease risk profile
should be determined for all patients and this should inform
management strategies.  Lifestyle modification and patient
education plays an essential role in the management
strategy.  Drug therapy:  First line – low dose thiazide-like
diuretics; second line – add one of the following: reserpine,
or β-blockers or ACE inhibitors or calcium channel blockers;
third line – add another second line drug or hydralazine or
α-blocker.  The guideline includes management of specific
situations, i.e. hypertensive emergency and urgency, severe
hypertension with target organ damage and refractory
hypertension (BP >160/95 mmHg on triple therapy),
hypertension in diabetes mellitus, etc.
Validity. Developed by the Working Groups established by
the Executive Committee of the Southern African
Hypertension Society with broader consensus meeting
endorsement.  The 2001 version was endorsed by the South
African Medical Association Guideline Committee.  The 2003
revisions were endorsed by the Executive Committee and a
wider Working Group.
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Hypertension is a costly and a major contributor to
cardiovascular disease (CVD).  In 1991, CVD accounted for 
R4 - R5 billion in direct and indirect costs.10 This expenditure
was 7.5% of the direct health care spending in South Africa.11
This guideline adopts the approach of a formal estimation of
cardiovascular risk which will allow the treatment of those
South Africans at highest risk and those who can gain
maximally from lifestyle and drug interventions at the lowest
cost, given South Africa’s limited national resources.  It is for
this reason that a new section has been added on sustainable
hypertension management and scarce resources.
The dilemma raised by changing the definition of
hypertension is highlighted by the 1998 South Africa
Demographic and Health Survey.12 In this survey 3.3 million
hypertensives were identified using the criterion of either a BP
of 160/95 mmHg or the taking of antihypertensive medication
(persons aged ≥ 15 years.)  By changing the BP criterion to the
lower level of 140/90 mmHg as suggested in this guideline a
further 3 million persons are added to the hypertensive
population.  This clearly has implications for the availability
and affordability of hypertensive care and was one of the main
reasons for holding the consensus meeting.  The implications of
not treating these patients must be considered.
2.  Objective
To promote evidence-based, accessible, and comprehensive
management of hypertension in adults by health care
professionals.
3.  Abbreviations
ABPM = ambulatory blood pressure monitoring; ACE-I =
angiotensin-converting enzyme inhibitor; ARB = angiotensin II
receptor blocker; BMI = body mass index; BP = blood pressure;
CCB = calcium channel blocker; CCD = clinical cardiovascular
disease;  CVD = cardiovascular disease; CHD = coronary heart
disease; DBP = diastolic blood pressure; ISH = isolated systolic
hypertension; SBP = systolic blood pressure; TC = total
cholesterol; TOD = target organ damage.
4. Measurement of blood pressure 
(new section)
BP measurement is a vital clinical sign but it is poorly
performed by all health care professional categories.  The
European Hypertension Society recently published detailed
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recommendations on the measurement of BP which the SAHS
Hypertension Working Group fully endorses.3
The previous recommendations regarding 24-hour
ambulatory BP monitoring (ABPM) are largely unchanged.
However, there have been advances in automatic devices and
in self- (home) measurement of BP, which have been driven by
the increasing recognition of mercury as an environmental
toxin.13
4.1  Generic measurement principles 
These recommendations are generic and apply equally to all
validated devices, especially clinic and self-measurement of BP,
e.g. arm position, posture of the patient, cuff size and the
number of readings that should be taken.  
If the BP is optimal (< 120/80 mmHg) on the first
measurement then further measurement is not necessary at
that time.  However, if the BP measurement is elevated, then
take the steps below to ensure accurate readings:
• BP is recorded using an approved device with the patient in
a sitting position (with the back supported, arm bared and
resting on a surface at heart level) for at least 5 minutes
before measurement.  Patients should not have smoked,
ingested caffeine-containing beverages or had food in the
previous 30 minutes. In persons aged over 60 years, those
with diabetes mellitus and others at risk, the BP should also
be recorded after standing for 1 minute to document
postural hypotension.
• An appropriate size cuff should be used: a standard cuff 
(12 cm) for a normal arm, a larger cuff (15 cm) for an arm
with a mid-upper circumference > 33 cm (the bladder
within the cuff should encircle 80% of the arm).  If an
undersized cuff is used, the BP can be overestimated
(undercuffing), and if the cuff and bladder are too large the
BP can be underestimated (overcuffing).
• Both systolic blood pressure (SBP) and diastolic blood
pressure (DBP) should be recorded. SBP is measured at the
first appearance of sound (phase I) and DBP is measured at
the disappearance of the sounds (phase V). Phase V is also
recommended in pregnancy.  In cardiac arrhythmias (e.g.
atrial fibrillation), the highest phase I, and lowest phase V
are recorded as the SBP and DBP respectively. There are
circumstances when both phase IV (muffling) and phase V
should be recorded, e.g. aortic regurgitation, pregnancy, and
severe anaemia.
• The BP recorded should be the average of two readings
taken 1 minute apart.  If the first two readings differ by 
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> 5 mmHg, additional readings should be taken.
• Repeat measurements should be performed on three
separate occasions when either the initial SBP is between
140 and 160 mmHg or the DBP is between 90 and 
100 mmHg. This should occur within 2 months to
determine if the patient should be diagnosed as
hypertensive.  All measurements should preferably be taken
at the same time of the day and using the same arm.
• The elderly may present special problems with BP
measurement because there may be considerable BP
variability, with periods of hypotension as well as
hypertension.  They may demonstrate postural and post-
prandial hypotension. The most common form of
hypertension is isolated systolic hypertension (ISH), due to
the arterial stiffening that occurs with ageing.  This
stiffening may cause pseudohypertension which may only
be diagnosed with specialist referral.
• The BP measurement device and its attachments (tubing,
cuff, valve) need to be serviced and calibrated at least every
2 years.
4.2  Mercury sphygmomanometer
There are increasing criticisms of the use of mercury
sphygmomanometers.  Mercury is inert and does not degrade.
Although it is not toxic to patients or operators when the
device is intact, mercury becomes a major environmental
hazard when it is discarded.13 There are international moves to
replace mercury sphygmomanometers with battery-operated
digital devices.  However, in South Africa and other
developing countries, there is concern about the availability of
these devices and the safe disposal of lead-containing batteries,
but if a mercury sphygmomanometer needs replacement a
validated oscillometric device should be considered.
4.3  Twenty-four-hour ABPM
ABPM is not part of routine BP evaluation but is increasingly
used worldwide.14 It is of value in the following circumstances
and for selected target groups: 
• Suspected white-coat hypertension
• White-coat effect
• Masked hypertension (reverse white-coat hypertension)
• Refractory hypertension
• Elderly patients in whom treatment is being considered
• Suspected nocturnal hypertension
• Type 1 diabetes mellitus
• Pregnancy
• Systolic and diastolic hypertension
• Ambulatory hypotension.
The ABPM measuring device must be rigorously validated
according to acceptable international standards before purchase
and must, together with its attachments (tubing, cuff, etc.), be
serviced on a regular basis.  In selected situations where ABPM
is not available, self-BP monitoring may be used as a
substitute.4
An up-to-date list of validated devices is available on a
recently established website (www.dableducational.com).15
4.4  Self-measurement of BP
Self-measurement of BP is recommended in selected
circumstances and for selected target groups:
• Suspected white-coat hypertension
• To guide antihypertensive medication
• The elderly
• Pregnancy
• Diabetes mellitus
• Refractory hypertension
• To improve compliance with treatment
• To predict outcomes.
The recommendation for the purchase of a device should
come from the patient’s medical practitioner.  The practitioner
is responsible for educating the patient on user procedure, and
the types of validated device that are available.  Not all devices
currently on the market have been validated according to
stringent international standards.  An up-to-date list of
validated devices may be found on a recently established
independent website, www.dableducational.com.15
Only upper arm devices are recommended, but even these
are unsuitable in patients with sustained arrhythmias. They
should not be used for BP measurement during exercise and
they are not as specific as ABPM for the diagnosis of white-coat
hypertension.
Patients must discuss any proposed change in drug
medication with their health care professional.
5.  Risk stratification
Cardiovascular risk factor stratification was accepted by all
delegates but there was considerable debate about whether the
adopted model should be qualitative or quantitative.
5.1  Rationale for cardiovascular risk evaluation
Consensus has been reached on the necessity of treating those
with known CVD, TOD, and for those with a SBP ≥ 180 mmHg
or DBP ≥ 110 mmHg.16 For those without CVD, TOD or very
high levels of BP the exact level of BP at which to treat has
changed over time.  This reflects the continuous risk associated
with BP.9,17 The recently published Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (JNC7)4 includes additional
CVD risk factors, e.g. obesity, in the treatment decision.  Table I
reflects the earlier Sixth Report of the Joint National Committee
on Prevention, Detection, Evaluation and Treatment of High
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Blood Pressure (JNCVI)18 as no mandate was given to update
the risk factors.
The Society remains committed to the format of the risk
factor model as outlined in JNCVI and JNC7 until there is wide
national consensus on a different CVD risk model by all
stakeholders (professionals, providers, government and health
care funders).  A number of risk factor charts are available, but
none relate specifically to the South African situation.  Any
consensus needs to address topics such as the weighting of BP
readings and other risk factors in relation to ethnic group and
the development of TOD.
5.2  Risk factors, target organ damage and clinical
cardiovascular disease
Listed below are the major risk factors and TOD/CCD.  Risk
factors that are modifiable (e.g. smoking and dyslipidaemia)
should be the target of lifestyle intervention and other
treatment as appropriate.  However, some TOD/CCD (e.g.
retinopathy and left ventricular hypertrophy) are not simply
complications of hypertension but also carry risk for morbidity
and disability.  Manage TOD/CCD as appropriate.  Table I
indicates risk stratification and the need for drug therapy when
the risk is increased and is based on JNCVI.18
5.2.1  Major risk factors
• Smoking
• Dyslipidaemia
• Diabetes mellitus
• Age > 60 years
• Sex (men, postmenopausal women)
• Family history of early onset of CVD (women aged < 65
years, men aged < 55 years).
5.2.2  TOD/CCD
• Left ventricular hypertrophy 
• Angina/prior myocardial infarction or ischaemia 
• Heart failure 
• Prior coronary revascularisation 
• Nephropathy (proteinuria with or without haematuria
and/or elevated serum creatinine) 
• Stroke or transient ischaemic attack 
• Retinopathy (exudates and/or haemorrhages and/or
papilloedema) 
• Peripheral arterial disease. 
5.3  Routine investigations 
• Body weight should be recorded at each visit when BP is
measured.
• Urine dipstick analysis for protein, blood and sugar should
be done at presentation:
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Table I. Risk stratification and treatment (adapted from JNCVI guideline18)
No risk factor or ≥ 1 major risk factor; TOD/CCD or diabetes
TOD/CCD no TOD/CCD mellitus with or without
other risk factors
High-normal Lifestyle modification Lifestyle modification Lifestyle modification
SBP 130 - 139 Low risk Low risk Drug therapy for those with
and/or heart failure, diabetes mellitus
DBP 85 - 89 or renal insufficiency
High risk
Stage I (mild) Lifestyle modification Lifestyle modification Lifestyle modification
SBP 140 - 159 for 6 - 12 months for 6-12 months Drug therapy
and/or Then drug therapy if needed and Then drug therapy as resources High risk
DBP 90 - 99 as resources permit permit
Low risk Medium risk
Stage II Lifestyle modification Lifestyle modification Lifestyle modification
(moderate) Recheck BP within 2 weeks, Recheck BP within 2 weeks, Drug therapy
SBP > 160 - 179 then drug therapy then drug therapy Very high risk
and/or Medium risk Medium risk
DBP 100 - 109
Stage III Asymptomatic severe Recheck BP after 1 hour
(severe)* hypertension Start drug therapy with
SBP > 180 Very high risk 2 agents
and/or Hypertensive urgency Start drug therapy with Very high risk
DBP > 110 Very high risk 2 agents
Hypertensive emergency Parenteral drug therapy
Very high risk*Refer when necessary.
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• If normal, repeat every 12 months.
• If abnormal, repeat at the next visit.
• If proteinuria ≥ 2+ or haematuria > 1+, then investigate
further.  If proteinuria is ≤ 2+, then monitor at least once a
year.
• If glycosuria and/or diabetic symptoms (polyuria/
polydipsia) are present, start dietary modification and
manage appropriately.
• If blood testing facilities are available, check urea, creatinine,
potassium, and glucose.
• Non-fasting total cholesterol should be measured in high-
risk groups.
• Perform a resting electrocardiogram when available.
6.  Goals of BP-lowering treatment
The goals of BP-lowering treatment vary according to TOD and
CCD as shown in Table II.19 These goals should be combined
with the recommended goals for ideal body weight, blood
sugar and lipid levels in patients with the metabolic syndrome
(see section 9.4.)
7.  Sustainable hypertension
management and scarce resources 
(new section)
The Society has given considerable time, thought and debate to
the very real concerns about the economic sustainability of
lifelong drug therapy.  The issues of affordability are
considered important factors in both the private and public
sectors of South Africa.  This becomes even more relevant
given the proposals for the holistic management of
hypertension, its complications and disease associations (see
section 9.4.)
The Society reiterates in the strongest possible terms the
importance of lifestyle modification at all stages of
hypertension.  If there are limited resources then drug
treatment may be delayed in mild (stage 1) hypertension until
there are one or more major risk factors or clinical
complications.  This is in line with World Health Organisation
and 2003 sub-Saharan Africa recommendations.21,22 Recent
studies emphasise the cost effectiveness of both lifestyle and
drug management in reducing CVD risk in both developed
and lesser developed regions of the world23 and the importance
of tight BP control in African Americans.24
In the current environment the price of antihypertensive and
other drugs fluctuates considerably irrespective of the market
sector.  Where possible, generic equivalents or generic drug
combinations are encouraged and the cheapest generic in a
class should be considered provided they are true equivalents.
The patient should not be changed from one generic to another
in the same class at frequent intervals solely on the basis of
lower price.  It is this Society’s concern that an overemphasis
on limited resources (when to introduce drug therapy, use of
generics, and inadequate level of BP control) may lead to
poorly managed hypertension with the undesirable
consequences of heart failure, stroke and chronic renal failure.
Best practice recommendations should be clearly stated and
compromises, based on limited resources, made deliberately
and transparently.
8. Management
The criterion for management is that BP has been measured
and recorded as elevated over a 2-month period for high-
normal and stage 1 hypertension.  Refer to Table I for details.
8.1  Lifestyle modification
All persons with hypertension should be encouraged to make
the following lifestyle changes as appropriate:
• Maintain ideal weight (BMI < 25): weight reduction in the
overweight patient  (BMI > 25)
• Salt restriction (e.g. remove the salt cellar from the table,
avoid processed foods, gradually reduce added salt in food
preparation), with increased potassium intake from fresh
fruits and vegetables
• Reduce alcohol intake to no more than two standard drinks
per day
• Follow a prudent eating plan, i.e. low fat, fibre and unrefined
carbohydrates, with adequate fresh fruit and vegetables
• Regular moderate aerobic exercise (e.g. 30 minutes brisk
walking 3 - 5 times/week)
• Stop smoking.
8.2  Drug therapy (new sections)
Table III lists the clinical considerations when selecting
antihypertensive drug therapy and Fig. 1 outlines the steps in
Table II. Goals of BP-lowering treatment
Stage BP level (mmHg)
All stages < 140/90 
Diabetes mellitus < 130/85 
Renal insufficiency
(serum creatinine > 220 µmol/l) < 130/85 
Proteinuria > 1 g/24 h < 125/75 
Congestive heart failure20 < 120/80 
Hypertensive emergency* Reduce mean arterial
(pulmonary oedema, pressure by 25% in the first
encephalopathy) 2 hours.  Aim for 
160/100 mmHg in 2 - 6 hours
*See section 10 for eclampsia and pre-eclampsia.
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the management of a patient with hypertension.  It is crucial to
ensure that the patient understands the importance of
adherence to the treatment regimen and brings back drug
containers and unused drugs.  This should be reinforced
frequently.  Patient empowerment and single daily dose
regimens improve compliance.  Where appropriate use fixed-
dose combinations.  Continued monitoring and management of
drug side-effects is essential.
The Society’s consistent recommendation has been that the
treatment of uncomplicated hypertension is with a low-dose
thiazide diuretic provided that the contraindications and
cautions in Table III are considered.  However, this
recommendation is now modified in the light of a recent trial28
and other evidence-based reviews.26 Step one drug therapy in
uncomplicated hypertension is a low-dose thiazide diuretic.
This Society’s recommendations for step two and step three
allow for considerations based on the cost of the various drug
classes and other patient-related factors such as the presence of
cardiovascular risk factors or CCD/TOD.
8.3  Compelling indications for a specific drug class
(new section)
Table IV outlines the compelling indications (high-risk
conditions) that require certain classes of antihypertensive
drugs based on randomised controlled trials.  In 2003 this
section was extensively revised in accordance with recent
evidence as indicated in the Table.  Previously the only
indication for the ARB class was in the case of ACE-I cough,2
but the indications are now wider.42 The compelling
indications for specific classes of drugs apply equally to
patients from any ethnic group.24
9. Management based on severity of
hypertension
9.1  Stage 1 DBP 90 - 99 mmHg and/or SBP 140 - 159
mmHg
• Start lifestyle modification and patient education.
• Repeat BP measurement over 6 months at 2 - 3-month
intervals.  If the BP falls to < 140/90 mmHg and there are no
risk factors, continue lifestyle changes.  Review annually,
ensuring the patient is not lost to follow-up.
• If the BP remains elevated at 6 - 12 months, start drug
treatment while continuing lifestyle modification provided
that the presence of other risk factors indicates that the
patient is at medium or higher CVD risk (Table I).
• In the presence of more than one major risk factor the
decision to treat patients at medium risk with drugs will
depend on the availability of resources.  In the presence of
Table III. Clinical considerations when selecting antihypertensive drug therapy (adapted from the WHO/ISH guidelines25)
Drug class Conditions/indications Contraindications Caution/limited value
Diuretics26 Heart failure Gout Diabetes mellitus
Elderly persons Dyslipidaemia
ISH Pregnancy
Black patients Erectile dysfunction
Reserpine27 Uncomplicated hypertension Depression
DO NOT USE with alcohol
β-blocker Angina and myocardial infarction Asthma & chronic obstructive Dyslipidaemia
Tachyarrhythmias pulmonary disease Diabetes mellitus type 1
Pregnancy Peripheral vascular disease Unstable heart failure
Diabetes mellitus type 2 Heart block Athletes & physically active patients
As monotherapy in black patients
ACE-I Heart failure Pregnancy As monotherapy in black patients
Left ventricular dysfunction after Hyperkalaemia 
myocardial infarction Bilateral renal artery stenosis
Diabetes mellitus with or without Angioedema
microalbuminuria/proteinuria
CCB Angina Heart block (verapamil or Congestive heart failure
(only long-acting Peripheral vascular disease diltiazem)
CCBs should be Elderly persons
used) ISH
Black patients 
ARB ACE-I cough (intolerance) Pregnancy As monotherapy in black patients
Left ventricular hypertrophy Hyperkalaemia
Diabetes mellitus type 2 with Bilateral renal artery stenosis
microalbuminuria OR proteinuria
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diabetes mellitus or TOD/CCD treatment should begin
immediately after diagnosing hypertension, i.e. after 2
months (the time taken to establish that the BP is elevated) or
sooner if the patient is symptomatic.
• Commence drug treatment with a low-dose thiazide-like
diuretic in the uncomplicated patient.
9.2  Stage 2 DBP 100 - 109 mmHg and/or SBP 160 -
179 mmHg 
• Start lifestyle modification and repeat BP measurements in 2
weeks
• If DBP is still 100 - 109 mmHg and/or SBP 160 - 179 mmHg,
start drug treatment while continuing lifestyle modification.
9.3  Stage 3  DBP ≥ 110 mmHg and/or SBP ≥ 180
mmHg
Persons with severe hypertension fall into three categories
which determine the urgency of treatment.  Patients should be
managed or referred to the appropriate level of care and
caregiver in accordance with local protocols.  Manage with
drug treatment and lifestyle modification.
9.3.1  Asymptomatic severe hypertension
These patients are asymptomatic and have severe hypertension
with or without evidence of TOD.  Keep the patient in the care
setting and repeat BP measurement after resting for 1 hour.  If
the second measurement is still elevated at the same level, start
oral therapy using two drugs together, one of which should be
a low-dose thiazide-like diuretic.  Follow up carefully and refer
as needed.
9.3.2  Hypertensive urgency
This level of hypertension is symptomatic with evidence of
TOD or grade III/IV retinopathy (malignant/accelerated
hypertension).  There are no immediate life-threatening
neurological or cardiac complications such as are seen in the
hypertensive emergencies (9.3.3).  Thrombotic (ischaemic)
stroke and intracerebral haemorrhage should be managed
according to the South African Stroke Therapy Clinical
Guideline (see box below).43 Ideally, all patients with
hypertensive urgency should be treated in hospital.
Table IV. Recommendations on compelling indications for a specific drug class
Any drug that lowers BP unless absolutely contraindicated (refer to Table III), will confer protection against TOD.  However, the following
classes of drugs have additional protective properties in the case of the listed CCD/TOD 
Compelling indications Drug class
Angina β-blocker OR CCB (rate lowering preferred) 29
Prior myocardial infarct or coronary artery disease β-blocker AND ACE-I (ARB if ACE-I intolerant).30 Verapamil if β-blocker 
contraindicated
Post myocardial infarction β-blocker AND ACE-I (ARB if ACE-I intolerant) AND aldosterone antagonist31
Heart failure ACE-I (ARB if ACE-I intolerant) AND certain β-blockers32 OR 
αβ-blocker AND spironolactone.33 Loop diuretics for volume overload.
Caution when using an ACE-I AND ARB AND β-blocker together34
Left ventricular hypertrophy (confirmed by ECG) ARB (preferred) OR ACE-I35
Stroke Low-dose thiazide-like diuretic AND ACE-I*36
Diabetes type 1 or 2 with or without evidence of ACE-I OR ARB37-41 — usually in combination with a diuretic*
microalbuminuria or proteinuria
Chronic kidney disease ACE-I OR ARB — usually in combination with a diuretic*
Isolated systolic hypertension Low-dose thiazide-like diuretic AND/OR long-acting CCB8
Pregnancy Methyldopa, prazosin, CCB (see section 10 on hypertension in pregnancy)
Prostatism α-blocker (not used as monotherapy for hypertension)
*The BP-lowering effects of ACE-Is and ARBs are greatly increased by the addition of a diuretic (thiazide-like or loop).
• Do not lower BP in acute stroke or use antihypertensive
medication unless the BP is SBP > 220 mmHg or the DBP
> 120 mmHg, as a rapid fall may aggravate cerebral
ischaemia and worsen the stroke.  
• If the BP is above these levels then treatment should aim
not to lower the BP by more than 15 - 20% in the first 24
hours.
• Treatment may be given orally but if the patient is unable
to swallow then the use of parenteral drugs may be
warranted.
• The use of parenteral drugs may also be warranted in the
setting of hypertensive emergencies (e.g. arterial
dissection, pulmonary oedema, hypertensive
encephalopathy) provided this takes place in a high-care
or ICU setting.  The best parenteral drugs appear to be
those that are easily titrated and have a minimal effect on
cerebral blood vessels, such as labetalol.  Sodium
nitroprusside should be administered in an ICU because
of its rapid onset of action.
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Commence treatment with two oral agents and aim to lower
the DBP to 100 mmHg slowly over 48 - 72 hours.  This BP
lowering can be achieved by:
• Long-acting CCB.
• ACE-I used in very low doses initially.  Avoid if there is
severe hyponatraemia (serum Na < 130 mmol/l indicates
hyper-reninaemia and hence BP may fall dramatically with
ACE-I).
• β-blockers.
• Diuretics may potentiate the effects of the other classes of
drugs when added.  Furosemide should be used if there is
renal insufficiency or signs of pulmonary congestion; its
effects may be potentiated by the concomitant use of
hydrochlorothiazide, particularly if the serum creatinine is
> 500 µmol/l.
9.3.3  Hypertensive emergency
This is a rare life-threatening situation requiring immediate
lowering of BP usually with parenteral therapy.  The true
emergency situation should preferably be treated by an
appropriate specialist.  Admit the patient to a high-care setting
for parenteral drug therapy (Table V) and close monitoring.
Do not lower the BP by > 25% within 30 - 120 minutes.  In the
next 2 - 6 hours, aim toward 160/100 mmHg.  This may be
achieved by the use of intravenous or oral drugs.
The life-threatening complications include:
• Hypertensive encephalopathy (severe headache, visual
disturbances, confusion, seizures, coma that may result in
cerebral haemorrhage)
• Unstable angina/myocardial infarction
• Acute left ventricular failure with severe pulmonary oedema
(extreme breathlessness at rest) 
• Excessive circulating catecholamines:
• phaeochromocytoma – rare cause of emergency
• food or drug interaction with monoamine oxidase
inhibitors 
• Eclampsia and severe pre-eclampsia 
• Acute nephritis with encephalopathy
• Acute aortic dissection.
9.4  Holistic management of the complicated patient
(new section)
A recently published European CVD prevention guideline6 is
more holistic in approach.  South Africa requires the
development of a similar document that takes into
consideration the special needs of its population.
Hypertension can seldom be managed in isolation from
other related chronic illnesses.  Obesity, dyslipidaemia and
Table V. Intravenous and oral drugs for hypertensive emergency 
Drug Dose Indications and precautions Effect on BP
Intravenous
Nitroglycerin 5 - 10 µg/min Especially useful for myocardial ischaemia BP lowering occurs in
(glyceryl trinitrate) 2 - 5 minutes
Dihydralazine 10 mg every 10 - 15 minutes until Avoid in patients with myocardial ischaemia BP lowering occurs
either BP is controlled or a in 10 minutes
maximum of 50 mg given
Sodium nitroprusside 0.25 - 10 µg/kg/min diluted in 5%  • Admission to ICU BP control is immediate
dextrose and adjust dose as • An intra-arterial BP line is desirable
necessary
Labetalol 2 mg/min to a total dose of • Use where emergency caused by 
1 - 2 mg/kg phaeochromocytoma
• Caution in acute pulmonary oedema
Furosemide 40 - 80 mg • Acts only for 6 hours
• Potentiates all of the above drugs
Oral (use only if IV drugs are not available)
Captopril 6.25 mg as a test dose • Other rapidly acting ACE I may be used BP lowering in 15 - 30
Increase to 25 mg if BP lowering starting with a low test dose minutes
is not obtained in 15 - 30 minutes • DO NOT USE if bilateral renal artery
stenosis is suspected
• DO NOT USE if pregnancy is suspected
Nifedipine 5 mg capsule • Preferred in black persons Risk of sudden BP fall
Dose can be repeated after 1 hour • Potentially dangerous: risk of sudden fall which can occur within
in BP which may precipitate CV events 15 - 30 minutes
• DO NOT USE in patients with known CHD 
or CVD
• BP must be continually monitored
ORIGINAL ARTICLES
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Begin or continue
lifestyle modification
BP > 140/90 mmHg?
STEP 1: INITIAL DRUG CHOICE
• Start with low dose or a long-acting
once-daily drug
• Titrate dose at 2-monthly intervals
GO TO STEP 2 THERAPY if any of the
following is present:
• BP not at goal after 2 months at step 1
• Worrying side-effects
GO TO STEP 3 THERAPY if any of the
following is present:
• BP not at goal after 2 months at step 3
• Worrying side-effects
If not controlled at STEP 3 after 2 more
months this is REFRACTORY
HYPERTENSION. Refer appropriately
BP goals are lower for
• diabetes mellitus
• cardiac failure
• renal disease
UNCOMPLICATED HYPERTENSION
Low-dose thiazide-like diuretic
OR
COMPELLING INDICATION FOR SPECIFIC
CLASS
See Box 1 below
STEP 2 DRUG THERAPY
Add one of the following to step 1
drug therapy
• low-dose thiazide-like diuretic
• Reserpine (< 0.1 mg daily)
• β-blocker
• ACE-I OR ARB
• long-acting CCB
• fixed dose combination
STEP 3 DRUG THERAPY
• ADD another drug from STEP 2
(above) OR
• hydralazine OR
• α-blocker
DO NOT USE MORE
THAN ONE DRUG FROM
THE SAME CLASS
BOX 1: COMPELLING INDICATIONS FOR A SPECIFIC CLASS OF DRUGS
• Angina: β-blocker OR CCB (rate lowering preferred).
• Prior MI or coronary artery disease: β-blocker AND ACE-I (ARB if ACE-I intolerant). Verapamil if
β-blocker contraindicated.
• Post MI: β-blocker AND ACE-I (ARB if ACE-I intolerant) AND aldosterone antagonist.
• Heart failure: ACE-I (ARB if ACE-I intolerant) AND certain β-blockers OR αβ-blocker AND spironolactone.
Loop diuretics for volume overload. Do not use an ACE-I AND ARB AND β-blocker together.
• LVH: ARB (preferred) OR ACE-I
• Stroke: Low-dose thiazide-like diuretic AND ACE-I
• Diabetes mellitus type 1 or 2 with or without microalbuminuria or proteinuria OR chronic kidney disease:
ACE-I or ARB usually in combination with a diuretic.
• ISH: Low-dose thiazide-like diuretic AND/OR long-acting CCB.
• Pregnancy: Methyldopa, prazosin, CCB (see section 10 on hypertension in pregnancy).
• Prostatism: α-blocker (not used as monotherapy for hypertension).
NO
YES
Fig. 1. Hypertension treatment algorithm.
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type 2 diabetes mellitus are increasingly prevalent and
commonly occur together with hypertension as the metabolic
syndrome.  Lifestyle modifications, drug therapy and the
targets of management should be broadened to include weight,
blood sugar and lipids as well as BP control (see section 6).
The Dietary Approaches to Stop Hypertension (DASH) low-
sodium diet will not only lower BP, but will also have a
favourable effect on weight, lipids and glycaemic control.44
There is mounting evidence that so-called normal lipid levels
may be inappropriately high in hypertensive patients and
certainly are so in patients with hypertensive complications,
e.g. stroke.23,45 Lipid-lowering therapy will increasingly become
part of standard drug therapy in both young and old.5
Intensive diet and exercise therapy and in some cases the use
of the biguanide, metformin, may be required to prevent the
progression to frank type 2 diabetes mellitus in hypertensive
patients with central obesity.
The indications for and cautions against the use of aspirin,
hormone replacement therapy and antioxidants are frequently
asked questions.  Low-dose aspirin should be used for
secondary prevention of transient ischaemic attacks, stroke and
myocardial infarction only once the BP is well controlled.
Hormone replacement therapy should only be prescribed for
those women with menopausal symptoms or those who are at
risk of osteoporosis.46 Antioxidants are of no benefit in
hypertensive patients.28
10.  Hypertension in pregnancy
Hypertensive conditions of pregnancy, particularly pre-
eclampsia, are multi-organ diseases requiring the monitoring of
renal, liver, placental and central nervous functions.
• BP > 140/90 mmHg on two occasions, at least 6 hours apart,
is abnormal.
• BP > 140/90 mmHg — treat with oral drugs
• BP > 180/110 mmHg should be treated as an hypertensive
emergency.
The presence of significant proteinuria (2+ on dipstick or 300
mg/24 h) in the first half of pregnancy usually indicates
underlying chronic renal disease; when it appears for the first
time in the second half of pregnancy, usually in association
with hypertension, pre-eclampsia is the most likely cause.
Patients with pre-eclampsia should be admitted to hospital.
10.1  Oral medication
• First drug: methyldopa, start with 500 mg 8-hourly,
increasing to 750 mg 8-hourly.
• Second drug: nifedipine, start with 10 mg 8-hourly,
increasing to 20 mg 8-hourly.  Note the contraindications and
cautions that should be taken when using nifedipine 
(Table V).
• Third drug: prazosin, start with 1 mg 8-hourly, increase to 7
mg 8-hourly.
For patients with chronic hypertension with no proteinuria,
low-dose thiazide works well as a second or third additional
drug.
10.2  Hypertensive emergency
Preload with 300 - 500 ml balanced crystalloid solution over 30
minutes.  Administer dihydralazine 6.25 mg slowly
intravenously over 2 minutes every 20 - 30 minutes or 6.25 mg
intramuscularly (by midwife).  Alternatively, 25 mg
dihydralazine may be diluted with 18 ml sterile water in a 
20 ml syringe.  Boluses of 2.5 - 5 mg (1-2 ml) are given
intravenously every 20 - 30 minutes.  Alternatively administer
a 10 mg nifedipine capsule immediately and, if necessary, 
20 - 30 minutes later.  This should be taken continuously in
patients receiving magnesium sulphate.
The goal should be to lower the BP to between140/90 and
150/100 mmHg.  Avoid ACE-I, reserpine, and diuretics in
patients with pre-eclampsia.  Only use β-blockers for very
specific indications.
11.  Patient education
The purpose of patient education is to empower the patient to
participate in good-quality hypertensive care.
• Patients need to understand hypertension and its
consequences if not treated adequately.  Involve them and
their families in treatment.
• Inform patients of the BP reading and their overall
cardiovascular risk at every visit and whether the BP is
controlled.
• Patients need to inform relevant medical authorities about
their hypertension and the medications they are taking for it.
• Encourage patients to request BP measurement at every visit
to a health care professional.
• Inform patients about the name and dose of medications
prescribed, the frequency of dosing, and the necessity for
regular lifelong use.
• Encourage a positive attitude to achieving therapeutic goals
and explain the need to add effective drugs stepwise in
sufficient doses to achieve the goal of therapy.
• Anticipate adverse effects and adjust therapy to prevent,
minimise or ameliorate adverse events.
• Encourage lifestyle modifications.
• Ask patients to return drug containers and unused drugs as
a measure of compliance/adherence to therapy.
• Emphasise adherence to management.
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12.  Refractory hypertension
Hypertension may be termed refractory when a therapeutic
plan that has included lifestyle measures and combination
drug treatment in adequate doses (triple-drug regimen
including a diuretic) has failed to lower BP to < 160/95 mmHg.
The causes of refractory hypertension are:25
• Unsuspected secondary cause (NB: coarctation, renal or
endocrine causes).
• Poor adherence to therapeutic plan.
• Continued intake of drugs that raise BP (e.g. inappropriate
use of non-steroidal anti-inflammatory drugs).
• Failure to modify lifestyle including:
• weight gain
• heavy alcohol intake (especially binge drinking).
• Volume overload due to:
• inadequate diuretic therapy
• progressive renal insufficiency
• high sodium intake.
The causes of spurious refractory hypertension are isolated
office (white-coat) hypertension and failure to use a large cuff
on a large arm.3
13. Ongoing management
13.1 Dose titration or stepwise increase should be carried out
after 2 months.
13.2 Once a stable target BP has been achieved, follow-up BP
measurement should be performed every 3 - 6 months.
13.3 Drug dose should be reduced if the patient presents with
symptoms of postural hypotension, i.e. dizziness or > 20
mmHg fall SBP on standing.
13.4 Refer the patient from the primary care level to higher
levels in the following circumstances:
• Young patients (18 - 30 years) 
• Pregnancy 
• Uncontrolled BP despite step 3 care (refractory hypertension) 
• Any patient with severe TOD and/or severe CCD 
• Hypertensive urgency or emergency 
14. Strategy implications (new section)
The Society acknowledges that the development and
publication of a clinical guideline is insufficient to ensure its
implementation and to change practice.47 The Society remains
committed to the development of an active multifaceted
implementation strategy with partners from all market sectors
and provider groups, including patient groups.
15. Disclaimer 
This national clinical guideline is for reference and education
only and is not intended to be a substitute for the advice of the
appropriate health care professional or for independent
research and judgement.  The SAHS accepts no responsibility
or liability arising from any information contained in or any
error or omission from the protocol or from the use of any
information contained in it.
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Annexure A: Hypertension Guideline
Working Groups 
The 2000 Guideline Working Group Members
Some Working Group members represented more than one
grouping.  Chairperson: R W Charlton. SAHS: H Kakaza, F J
Milne (Principal author), K P Mokhobo, M Mpe, D P Naidoo, G
Norton, L Opie, V J Pinkney-Atkinson (guideline facilitator), P
Sareli, Y K Seedat, H C Seftel, K Steyn, D R Taylor, Y Veriava, D
J V Weich. National Department of Health, Directorate Chronic
Diseases, Disabilities and Geriatrics: C C Kotzenberg, A
Croasdale. SA Heart Association: A J Dalby.  Society of General
Practice: S Mazaza. SA Academy of Family Practice: 
L Geffen. Neurological Association of SA and Stroke
Foundation of SA: A Bryer.  Heart Foundation of SA: G Pappas.
Lipid and Atherosclerosis Society of SA: K Steyn.  Medical
Advisors Group: H C Seftel, F J Milne. National Pathology
Group: P Cole.  SA Renal Society: A Meyers.  Society for
Endocrinology, Metabolism and Diabetes of SA: A Motala.
SAMA: P Mavengere (Guideline Committee).  SA Society of
Obstetricians and Gynaecologists: H J Odendaal.  SA Society of
Occupational Medicine: A Combrinck.  Invited participant: T A
Gaziano.  Private sector health funders: Medscheme: B Taylor;
Qualsa Healthcare: A van den Heever; Discovery Health: R
Klein, N Butkow. Observer Delegates: Aventis: R Potgieter;
Bayer Healthcare: L Anderson; Boehringer Ingelheim: T
Kruger; Bristol-Myers-Squibb: D Webb; Merck Generics: A
Becker; Novartis: M Frey; Pfizer: T McCoy; Roche Products: M
Newton; Sanofi-Synthelabo: M Palane; Servier Laboratories: 
M Parkin.
The 2003 Guideline Update Working Group
SAHS Executive Committee participated in the revision
process: A Maseko, S Middlemost, F J Milne (Working Group
Chairperson, Editor), K P Mokhobo, P S Mntla, M Mpe, D P
Naidoo, G Norton, L H Opie, V J Pinkney-Atkinson (Editor), 
B Rayner (President), Pinhas E Sareli, Y K Seedat, H C Seftel, 
K Steyn, B van Rensburg, Y Veriava, A J Woodiwiss.
International speakers at the 13th Scientific meeting: A Mimran
(France), K Narkiewicz (Poland), E O’Brien (Republic of
Ireland), N Poulter (United Kingdom), K S Reddy (India), 
B Waeber (Switzerland).
South African Special Interest Groups: M Connor (SA Stroke
Foundation); F J Raal (Society for Metabolism, Endocrinology
of South Africa and Lipid and Atherosclerosis Society of South
Africa), A J Dalby (SA Heart Association).
African Hypertension Special Interest Groups: O Oosthuizen
(Namibia); B Onwubere (Nigeria); A Damasceno
(Mozambique).
Invited Local National Department of Health Delegates: 
C C Kotzenberg, A Croasdale.
Annexure B: Methodology 
In 1999 the Executive Committee of the SAHS revised the 1995
guideline and it was submitted to the South African Medical
Association’s (SAMA) Guideline Committee for endorsement.
Provisional endorsement as a national guideline was given
provided that certain recommendations were made.  This led to
a facilitated guideline development process in 2000 in
conjunction with the Southern African Hypertension Society.
On 14 May 2000, a nationally representative hypertension
consensus meeting was held in Gauteng.  Participants were
invited as representatives of professional, government and
consumer groups with an interest in the hypertension field.  
All participants received a revised copy of the draft guideline
developed previously together with the relevant references
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before the meeting.  The meeting was chaired by a neutral
chairperson.  The purpose of the meeting was to consider the
content of the draft guideline and either endorse or amend the
document.  The proceedings were audio recorded and
transcribed for future reference.
The endorsement document was revised according to the
proceedings of the national consensus meeting and also
incorporates a further series of comments circulated after the
meeting.  The endorsement draft document was circulated to
all participants and many other interested persons
approximately 8 weeks after the meeting. 
Amendments will be made to the guideline where there is
sufficient need.  All major debates and areas where it was not
possible to come to agreement will be highlighted.  The 2000
guideline was endorsed by the SAMA Guideline Committee (in
2003 this body became defunct.)
Equal financial sponsorship was received from: Aventis,
Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers-Squibb,
Merck Generics, Novartis, Pfizer, Roche Products, Sanofi-
Synthelabo and Servier Laboratories.  The grants were
unconditional precluding the unethical influence of the content
of the guideline by sponsors.  All funds were paid directly into
the SAHS accounts and all disbursements made from that
fund. 
In 2002 the SAHS Executive commenced the review of
selected guideline sections: BP measurement, compelling
indications.  New sections on holistic and sustainable
hypertension management, and strategy implications were also
added.  At the 13th Biennial Congress of the Society (March
2003), a Working Group was assembled to consider interim
modifications to the guidelines based on evidence and
presentations (participants listed in Annexure A).  The
pharmaceutical industry was not represented at the meeting,
nor was any sponsorship raised for the meeting. Boehringer
Ingelheim made available the services of its Medical Librarian,
Ms Sylvia Bezuidenhout, who performed the required
literature searches and obtained copies of publications. 
The amendments were posted on the SAHS website
(www.hypertension.org.za) for comment and were sent out to
the Executive Committee.  Further comment was sought from
local experts in certain sections.  
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